<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2664-3243</journal-id>
<journal-title><![CDATA[Vive Revista de Salud]]></journal-title>
<abbrev-journal-title><![CDATA[Vive Rev. Salud]]></abbrev-journal-title>
<issn>2664-3243</issn>
<publisher>
<publisher-name><![CDATA[CET-BOLIVIA]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2664-32432021000300116</article-id>
<article-id pub-id-type="doi">10.33996/revistavive.v4i12.112</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Factores de riesgo y complicaciones cardiovasculares en pacientes por alteraciones de fosforo y calcio]]></article-title>
<article-title xml:lang="en"><![CDATA[Risk factors and cardiovascular complications in patients with phosphorus and calcium disorders]]></article-title>
<article-title xml:lang="pt"><![CDATA[Factores de risco e complicações cardiovasculares em doentes com perturbações do fósforo e do cálcio]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Romero Merelo]]></surname>
<given-names><![CDATA[Carolina Carolay]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Esteves Echanique]]></surname>
<given-names><![CDATA[David William]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ríos Delgado]]></surname>
<given-names><![CDATA[Luis Aarón]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Reyes Bravo]]></surname>
<given-names><![CDATA[Karl Enrique]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,aff1  ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2021</year>
</pub-date>
<volume>4</volume>
<numero>12</numero>
<fpage>116</fpage>
<lpage>126</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_arttext&amp;pid=S2664-32432021000300116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_abstract&amp;pid=S2664-32432021000300116&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.bo/scielo.php?script=sci_pdf&amp;pid=S2664-32432021000300116&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen La enfermedad renal crónica es un problema de salud pública a nivel mundial y se define como una anormalidad patológica del riñón como hematuria o proteinuria, o una reducción de la tasa de filtrado glomerular menor a 60ml-min por más de tres meses. En todos los estudios la prevalencia a esta enfermedad va aumentando debido a que sus principales causas diabetes e hipertensión se han convertido en pandemias.  Objetivo.  Demostrar los factores de riesgo y complicaciones cardiovasculares en pacientes por alteraciones minerales y óseas.  Métodos.  Se realizó un estudio descriptivo transversal en los pacientes del Instituto del riñón INRIDI San Martin de Enero a Nov del 2019, los métodos de investigación implementados fueron analítico y cualitativo- cuantitativo. El universo estuvo constituido por los 253 pacientes de la clínica de diálisis San Martin se obtuvo como muestra 70 pacientes basado en los criterios de exclusión.  Resultados.  Se halló que el 94.2 % de los pacientes estudiados estuvieron en el grupo de casos sin hipercalcemia, así mismo 58.55% sentaron en el grupo con hiperfosfatemia. Entre los factores de riesgo se demostró la prevalencia en el sexo masculino, la hipertensión, diabetes y la dislipidemia.  Conclusiones . La frecuencia de cambios en el metabolismo mineral y óseo en pacientes con ERC es muy variable, y este estudio revela aspectos epidemiológicos que permiten reconocer los problemas actuales de la enfermedad que viabilizaran reducir el riesgo de eventos cardiovasculares y mejorar la calidad de vida de los pacientes.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract Chronic kidney disease is a worldwide public health problem and is defined as a pathological abnormality of the kidney such as hematuria or proteinuria, or a reduction of the glomerular filtration rate to less than 60 ml-min for more than three months. In all studies the prevalence of this disease is increasing because its main causes diabetes and hypertension have become pandemics.  Objective.  To demonstrate the risk factors and cardiovascular complications in patients with mineral and bone alterations.  Methods.  A cross-sectional descriptive study was conducted in patients of the Instituto del riñón INRIDI San Martin from January to Nov 2019, the research methods implemented were analytical and qualitative-quantitative. The universe was constituted by the 253 patients of the San Martin dialysis clinic, 70 patients were obtained as a sample based on the exclusion criteria. Results:  Results.  It was found that 94.2% of the patients studied were in the group of cases without hypercalcemia, and 58.55% were in the group with hyperphosphatemia. Among the risk factors, the prevalence in the male sex, hypertension, diabetes and dyslipidemia was demonstrated.  Conclusions . The frequency of changes in bone and mineral metabolism in patients with CKD is highly variable, and this study reveals epidemiological aspects that allow us to recognize the current problems of the disease that will make it feasible to reduce the risk of cardiovascular events and improve the quality of life of patients.]]></p></abstract>
<abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Resumo A doença renal crónica (CKD) é um problema de saúde pública mundial e é definida como uma anomalia patológica do rim, como a hematúria ou proteinúria, ou uma redução da taxa de filtração glomerular para menos de 60ml-min durante mais de três meses. Em todos os estudos, a prevalência desta doença está a aumentar porque as suas principais causas de diabetes e hipertensão se tornaram pandemias.  Objectivo.  Demonstrar os factores de risco e as complicações cardiovasculares em doentes com doenças minerais e ósseas.  Métodos.  Foi realizado um estudo descritivo transversal em pacientes do instituto renal San Martin INRIDI de Janeiro a Novembro de 2019, os métodos de investigação implementados foram analíticos e qualitativos-quantitativos. O universo consistia em 253 pacientes da clínica de diálise de San Martin, 70 pacientes foram obtidos como amostra com base nos critérios de exclusão.  Resultados.  Verificou-se que 94,2% dos doentes estudados se encontravam no grupo de casos sem hipercalcemia, e 58,55% estavam no grupo com hiperfosfatemia. Entre os factores de risco, foi demonstrada a prevalência de hipertensão, diabetes e dislipidemia no sexo masculino.  Conclusões . A frequência das alterações do metabolismo ósseo e mineral em doentes com CKD é altamente variável, e este estudo revela aspectos epidemiológicos que nos permitem reconhecer os problemas actuais da doença que tornarão viável a redução do risco de eventos cardiovasculares e a melhoria da qualidade de vida dos doentes.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[ERC]]></kwd>
<kwd lng="es"><![CDATA[Filtrado glomerular]]></kwd>
<kwd lng="es"><![CDATA[Hipertensión]]></kwd>
<kwd lng="en"><![CDATA[ERC]]></kwd>
<kwd lng="en"><![CDATA[Glomerular filtration rate, Hypertension]]></kwd>
<kwd lng="pt"><![CDATA[ERC]]></kwd>
<kwd lng="pt"><![CDATA[Taxa de filtração glomerular]]></kwd>
<kwd lng="pt"><![CDATA[Hipertensão arterial]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Loaiza]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Condori]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Quispe]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pinares]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Atamari]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortalidad y factores asociados en pacientes con enfermedad renal crónica en hemodiálisis en un hospital peruano]]></article-title>
<source><![CDATA[Rev haban cienc méd]]></source>
<year></year>
<volume>18</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>164-75</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Francis]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Allen]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Kuo]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Cardenas]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Feldman]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Establishing a higher priority for chronic kidney disease in Peru]]></article-title>
<source><![CDATA[Lancet Glob Heal]]></source>
<year>2016</year>
<volume>4</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>17-8</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bernuy]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Gonzales]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metabolismo mineral óseo en pacientes con enfermedad renal crónica: revisión sobre su fisiopatología y morbimortali¬dad]]></article-title>
<source><![CDATA[Rev Peru Med Exp Salud Publica]]></source>
<year>2015</year>
<volume>32</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>326-34</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Trujillo]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sierra]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Osorno]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Alteraciones del metabolismo mineral y óseo asociadas a la enfermedad renal crónica]]></article-title>
<source><![CDATA[Rev Med MD]]></source>
<year></year>
<volume>6</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>151</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stevens]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Schmid]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Greene]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zhang]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Beck]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Froissart]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Souchay]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Sotolongo]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Álvarez]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Castillo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Complicaciones cardiovasculares y sus factores de riesgo en pacientes adultos portadores de Enfermedad Renal Crónica]]></article-title>
<source><![CDATA[Rev Panorama Cuba y Salud]]></source>
<year></year>
<volume>14</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>3-10</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitchell]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<source><![CDATA[La OPS/OMS y la Sociedad Latinoamericana de Nefrología llaman a prevenir la enfermedad renal y a mejorar el acceso al tratamiento. Pan American Health Organization]]></source>
<year></year>
<page-range>1-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gonzalez]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rosa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Pecoits]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreiro]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Burden of disease: prevalence and incidence of ESRD in Latin America]]></article-title>
<source><![CDATA[Clin Nephrol]]></source>
<year></year>
<volume>7</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>3-6</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Afsar]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Turkmen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Covic]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Kanbay]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[An update on coronary artery disease and chronic kidney disease]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Díaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Robalino]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lucero]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<source><![CDATA[Comportamiento epidemiológico en pacientes con enfermedad renal crónica terminal en Ecuador]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Alcázar AR]]></surname>
<given-names><![CDATA[Orte L]]></given-names>
</name>
<name>
<surname><![CDATA[González E]]></surname>
<given-names><![CDATA[Górriz JL]]></given-names>
</name>
<name>
<surname><![CDATA[Navarro JF]]></surname>
<given-names><![CDATA[Martín de Francisco]]></given-names>
</name>
<name>
<surname><![CDATA[A. L.]]></surname>
<given-names><![CDATA[Egocheaga MI]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de consenso SEN-semFYC sobre la enfermedad renal crónica]]></article-title>
<source><![CDATA[Nefrologia]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B12">
<nlm-citation citation-type="">
<source><![CDATA[Nefrologia]]></source>
<year></year>
<volume>34</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>243-62</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Husseini]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kaskar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Goldstein]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Chronic kidney disease and stroke]]></article-title>
<source><![CDATA[Adv Chronic Kidney Dis]]></source>
<year></year>
<volume>21</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>500-8</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ricardo]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lash]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Fischer]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Lora]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Budoff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Keane]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cardiovascular disease among hispanics and non-hispanics in the chronic renal insufficiency cohort (CRIC) study]]></article-title>
<source><![CDATA[Clin J Am Soc Nephrol]]></source>
<year></year>
<volume>6</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2121-3</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pérez]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Herrera]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Almaguer]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Situación de la enfermedad renal crónica en Cuba]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Medellín]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carrillo]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Soporte social percibido y calidad de vida de personas con enfermedad renal crónica sometidas a trasplante renal]]></article-title>
<source><![CDATA[Rev Av en Enfermería]]></source>
<year>2014</year>
<volume>32</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>206-16</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sánchez-Celaya]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Tranche]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Documento de consenso sobre la enfermedad renal crónica. S.E.N-semFYC]]></article-title>
<source><![CDATA[Atención Primaria]]></source>
<year>2014</year>
<numero>46</numero>
<issue>46</issue>
<page-range>453-4</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Dolores]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<source><![CDATA[Alteraciones del Metabolismo Mineral: Calcio, Fósforo, PTH, Vitamina D, FGF-23, Klotho]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chia-Ter]]></surname>
<given-names><![CDATA[Szu-Ying Lee]]></given-names>
</name>
<name>
<surname><![CDATA[Wei-Shun Yang]]></surname>
<given-names><![CDATA[Chung-Yen]]></given-names>
</name>
<name>
<surname><![CDATA[Chih-Kang Chiang]]></surname>
<given-names><![CDATA[Jenq-Wen Huang]]></given-names>
</name>
<name>
<surname><![CDATA[Kuan-Yu Hung]]></surname>
</name>
</person-group>
<source><![CDATA[Serum vitamin D levels are positively associated with variccella zoster inmunity in chronic dialysis patients]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ugarte]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Carranza]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Nefropatía Diabética]]></article-title>
<source><![CDATA[Rev Chil pediatría]]></source>
<year></year>
<volume>73</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>455-60</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cohen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Funch]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Urena]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Bone fragility in patients with chronic kidney diseases]]></article-title>
<source><![CDATA[Endocr Connect]]></source>
<year>2020</year>
<volume>9</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>93-101</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lioufas]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Sm Chen]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hawley]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Pedagogos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Effect of phosphate-lowering therapy on cardiac structure and function-a sub-study of the improve-CKD trial]]></article-title>
<source><![CDATA[Nephrology]]></source>
<year></year>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Puruncajas]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<source><![CDATA[Prevalencia de hiperparatiroidismo secundario a enfermedad renal crónica estadio cinco en pacientes bajo tratamiento de hemodiálisis en el centro de hemodiálisis vyr durante el 2017]]></source>
<year></year>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
